Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025983) BCMA MONOCLONAL ANTIBODY-DRUG CONJUGATE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025983 International Application No.: PCT/IB2018/055753
Publication Date: 07.02.2019 International Filing Date: 31.07.2018
IPC:
C07K 16/28 (2006.01) ,A61K 47/68 (2017.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
[IPC code unknown for A61K 47/68]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
MEDIMMUNE, LLC [US/US]; One Medimmune Way Gaithersburg, Maryland 20878, US
Inventors:
KINNEER, Krista; US
VARKEY, Reena; US
XIAO, Xiaodong; US
HURT, Elaine M.; US
TICE, David; US
Agent:
DISE, Rebecca S.; US
Priority Data:
62/539,82501.08.2017US
62/596,19408.12.2017US
Title (EN) BCMA MONOCLONAL ANTIBODY-DRUG CONJUGATE
(FR) CONJUGUÉ ANTICORPS MONOCLONAL-MÉDICAMENT DIRIGÉ CONTRE BCMA
Abstract:
(EN) The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
(FR) L'invention concerne un conjugué anticorps-médicament (ADC) comprenant un anticorps monoclonal, ou un fragment de liaison à l'antigène de celui-ci, dirigé contre l'antigène de maturation des lymphocytes B (BCMA) conjugué à une cytotoxine. L'invention concerne également des compositions comprenant le conjugué anticorps-médicament et des procédés de destruction de cellules de myélome multiple (y compris des cellules souches de myélome multiple) qui expriment BCMA par la mise en contact de cellules de myélome multiple avec l'ADC.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)